[go: up one dir, main page]

GB201006166D0 - Compounds for the treatment of metabolic disorders - Google Patents

Compounds for the treatment of metabolic disorders

Info

Publication number
GB201006166D0
GB201006166D0 GBGB1006166.1A GB201006166A GB201006166D0 GB 201006166 D0 GB201006166 D0 GB 201006166D0 GB 201006166 A GB201006166 A GB 201006166A GB 201006166 D0 GB201006166 D0 GB 201006166D0
Authority
GB
United Kingdom
Prior art keywords
compounds
treatment
metabolic disorders
metabolic
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1006166.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Priority to GBGB1006166.1A priority Critical patent/GB201006166D0/en
Publication of GB201006166D0 publication Critical patent/GB201006166D0/en
Priority to PCT/EP2011/055864 priority patent/WO2011128394A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1006166.1A 2010-04-14 2010-04-14 Compounds for the treatment of metabolic disorders Ceased GB201006166D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1006166.1A GB201006166D0 (en) 2010-04-14 2010-04-14 Compounds for the treatment of metabolic disorders
PCT/EP2011/055864 WO2011128394A1 (en) 2010-04-14 2011-04-13 3-substituted 5-(pyrrolidine-1-carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1006166.1A GB201006166D0 (en) 2010-04-14 2010-04-14 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
GB201006166D0 true GB201006166D0 (en) 2010-05-26

Family

ID=42236248

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1006166.1A Ceased GB201006166D0 (en) 2010-04-14 2010-04-14 Compounds for the treatment of metabolic disorders

Country Status (2)

Country Link
GB (1) GB201006166D0 (en)
WO (1) WO2011128394A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150225T1 (en) * 2010-10-14 2015-06-19 Daiichi Sankyo Company, Limited Acylbenzene derivative
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2718279B1 (en) 2011-06-09 2016-08-10 Rhizen Pharmaceuticals SA Novel compounds as modulators of gpr-119

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
CA2418656C (en) * 2000-08-10 2011-02-01 Mitsubishi Pharma Corporation Proline derivatives and use thereof as drugs
AU2003224632A1 (en) 2002-03-01 2003-09-16 Smithkline Beecham Corporation Hppars activators
BRPI0418149A (en) 2003-12-24 2007-04-17 Prosidion Ltd heterocyclic derivatives as gprc receptor agonists
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
NZ556017A (en) 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
CA2613236A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
MX2007016508A (en) 2005-06-30 2008-03-04 Prosidion Ltd Gpcr agonists.
MX2008012814A (en) 2006-04-06 2008-10-17 Prosidion Ltd Heterocyclic gpcr agonists.
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
PE20081849A1 (en) 2007-01-04 2009-01-26 Prosidion Ltd PIPERIDIN-4-IL-PROPOXY-BENZAMIDE DERIVATIVES AS GPCR AGONISTS
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
RS52065B (en) 2007-01-04 2012-06-30 Prosidion Ltd PIPERIDINSKI GPCR AGONIST
AR064735A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND
US20100048625A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008157330A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
CA2693169C (en) 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009034388A1 (en) 2007-09-10 2009-03-19 Prosidion Limited Compounds for the treatment of metabolic disorders
KR101136774B1 (en) 2007-10-18 2012-04-19 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 Metal covered polyimide composite, process for producing the composite, and process for producing electronic circuit substrate
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
CL2009000782A1 (en) * 2008-03-31 2010-04-30 Metabolex Inc Method comprising a substituted oxymethylene aryl derivative compound, dpp-iv inhibitors; and its use in the treatment of diabetes and lowering of triglycerides, among other diseases.
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
JP2011527331A (en) 2008-07-10 2011-10-27 プロシディオン・リミテッド Piperidinyl GPCR agonist
ATE557024T1 (en) 2008-07-10 2012-05-15 Prosidion Ltd PIPERIDINE COMPOUNDS AS GPCR AGONISTS
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds

Also Published As

Publication number Publication date
WO2011128394A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
ZA201403795B (en) Formulations for the treatment of diabetes
KR102297388B9 (en) Use of akkermansia for treating metabolic disorders
GB0904285D0 (en) Compounds for the treatment of metabolic disorders
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
GB0904287D0 (en) Compounds for the treatment of metabolic disorders
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
GB0904284D0 (en) Compounds for the treatment of metabolic disorders
IL225896A0 (en) Treatment of mecp2-associated disorders
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
BR112013015048A2 (en) composition for the treatment of metabolic disorders
PL2882724T3 (en) Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac
GB201006167D0 (en) Compounds for the treatment of metabolic disorders
IL234616A0 (en) Herbal composition for the treatment of metabolic disorders
GB201006166D0 (en) Compounds for the treatment of metabolic disorders
IL234796B (en) Compounds for the treatment of ischemia-reperfusion-related diseases
EP2240024A4 (en) Compounds for the treatment of metabolic disorders
GB201019482D0 (en) Compounds for the treatment of metabolic disorders
GB201006164D0 (en) Compounds for the treatment of metabolic disorders
GB201004740D0 (en) Compounds for the treatment of metabolic disorders
GB201006163D0 (en) Compounds for the treatment of metabolic disorders
GB201004744D0 (en) Compounds for the treatment of metabolic disorders
GB201004742D0 (en) Compounds for the treatment of metabolic disorders
GB201004741D0 (en) Compounds for the treatment of metabolic disorders
GB201106154D0 (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)